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Protocol
AbstrACt
Introduction This study is designed to determine whether 
a full randomised controlled trial (RCT) examining the 
clinical effectiveness and safety of total knee replacement 
surgery with or without a tourniquet is warranted and 
feasible.
Method and analysis Single centre, patient-blinded 
and assessor-blinded RCT. A computer-generated 
randomisation service will allocate 50 participants into 
one of two trial treatments, surgery with or without 
a tourniquet. The primary objective is to estimate 
recruitment, crossovers and follow-up of patients. All 
patients will have an MRI scan of their brain preoperatively 
and day 1 or 2 postoperatively to identify ischaemic 
cerebral emboli (primary clinical outcome). Oxford 
Cognitive Screen, Montreal Cognitive Assessment and 
Mini-Mental State Examination will be evaluated as 
outcome tools for measuring cognitive impairment at days 
1, 2 and 7 postoperatively. Thigh pain, blood transfusion 
requirements, venous thromboembolism, revision surgery, 
surgical complications, mortality and Oxford knee and five-
level EuroQol-5D scores will be collected over 12 months. 
Integrated qualitative research study: 30 trial patients 
and 20 knee surgeons will take part in semistructured 
interviews. Interviews will capture views regarding the 
pilot trial and explore barriers and potential solutions to 
a full trial. Multicentre cohort study: UK National Joint 
Registry data will be linked to Hospital Episode Statistics 
to estimate the relationship between tourniquet use and 
venous thromboembolic event, length of hospital stay, risk 
of revision surgery and death. The study will conclude 
with a multidisciplinary workshop to reach a consensus on 
whether a full trial is warranted and feasible.
Ethics and dissemination National Research Ethics 
Committee (West Midlands-Edgbaston) approved this 
study on 27 January 2016 (15/WM/0455). The study 
is sponsored by University of Warwick and University 
Hospitals Coventry and Warwickshire. The results will be 
disseminated via high-impact peer-reviewed publication.
trial registration number ISRCTN20873088; Pre-results.
IntroduCtIon
Arthritis of the knee can cause pain and 
restrict activities of daily living. Total knee 
replacement (TKR) surgery is a surgical 
procedure aimed at resolving the symptoms 
of end-stage knee arthritis.1 TKR surgery is 
typically undertaken with the aid of a tourni-
quet. A tourniquet acts as an occlusive device 
around the thigh with the aim of reducing 
blood flow distally. In the UK, over 90% of 
TKRs are performed with a tourniquet.2 3 
Anecdotally, surgeons believe using a tourni-
quet provides a bloodless field to improve the 
operative field of view.4 Many surgeons 
also believe using a tourniquet improves 
the quality of the cementation of the knee 
implants5 by reducing bone bleeding and 
allowing better interdigitation of the cement 
into the porous bone.
Previous systematic reviews have concluded 
that the use of tourniquets did not reduce 
intraoperative or postoperative blood loss6 
and were associated with significant compli-
cations including venous thromboembolic 
events (VTEs),5 wound infection, bruising 
and nerve palsy.5 7
In TKR surgery, a tourniquet causes both 
arterial and venous stasis for the duration it 
is applied. It is therefore unsurprising that 
the use of a thigh tourniquet might increase 
the risk of postoperative VTE.2 However, VTE 
may not be the only thromboembolic risk 
associated with using a tourniquet. Research 
has demonstrated that systemic emboli can 
occur when the tourniquet is deflated with 
up to a 60% prevalence of echogenic mate-
rial in the circle of Willis.8 9 Emboli may reach 
the systemic circulation through the pulmo-
nary capillaries or the opening of other 
strengths and limitations of this study
 ► Comprehensive feasibility research.
 ► Clearly defined outcome measures.
 ► Patient blinding.
 ► Single-centre design with small sample size.
 ► Absence of blinding among clinicians delivering the 
intervention.
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pulmonary vessels.9 The prevalence of postoperative 
cognitive impairment after TKR is high with reports in the 
literature varying from 41%–75% at 7 days to 18%–45% at 
3 months, and this may in part be explained by cerebral 
emboli if they are occurring following the release of a 
tourniquet.10
Although studies have demonstrated that tourniquets 
do not substantially reduce blood loss and may increase 
complications, a review of these studies, by Alcelik et 
al7, identified significant design flaws, including issues 
with randomisation, blinding and the absence of clearly 
defined outcome measures. Furthermore, no controlled 
studies have addressed or quantified one of the most 
potentially serious risks associated with tourniquet, 
which are cerebral emboli, and any resultant cognitive 
impairment.
There may be problems with running a trial that 
involves recruiting patients who, once it is explained, may 
not be prepared to accept the potential risks of surgery 
with a tourniquet. Equally, surgeons may be not willing to 
change surgical practice for a randomised trial.
We designed a feasibility study, which includes three 
separate but integrated projects: (A) pilot randomised 
controlled trial (RCT), (B) integrated qualitative research 
study and (C) retrospective multicentre cohort study.
The objective of the safety and feasiblity evalua-
tion of tourniquets for total knee replacement surgery 
(SAFE-TKR) study is to establish whether a full RCT eval-
uating tourniquets in knee replacement surgery is 
warranted and feasible.
PIlot rCt
The primary objective of the pilot trial is to estimate 
recruitment, crossover and follow-up of patients for a full 
trial.
secondary objectives
 ► evaluate MRI for detecting postoperative ischaemic 
cerebral emboli, including an estimate of the size and 
direction of any effect;
 ► evaluate tools for detecting postoperative cognitive 
impairment. These tools include Mini-Mental State 
Examination (MMSE), Montreal Cognitive Assess-
ment (MoCA) and the Oxford Cognitive Screen 
(OCS), including an estimate of the size and direction 
of any effect;
 ► evaluate other candidate primary/coprimary/
secondary outcome measures for assessment within a 
larger trial including: thigh pain, symptomatic VTE, 
mortality, revision surgery, blood transfusion require-
ments, function and health-related quality of life. To 
include obtaining estimates for the SD of continuous 
outcome variables and differences in proportions for 
categorical outcome variables in order to facilitate 
potential sample size calculations for a full trial;
 ► test and optimise patient information material and 
the patient pathway for a full trial.
Method
The protocol was produced in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials guidelines.11 The trial will be reported 
in line with the Consolidated Standards of Reporting 
Trials (CONSORT) statement.12
A single-centre two-arm pilot RCT will be performed. 
All patients under the care of 13 participating orthopaedic 
consultants at University Hospital Coventry and Warwick-
shire National Health Service (NHS) trust are potentially 
eligible for entry into the trial. The following eligibility 
criteria will be implemented for patient selection:
Inclusion criteria
 ► undergoing a primary unilateral TKR
 ► age ≥18 years
 ► able to give written informed consent and to partic-
ipate fully in the interventions and follow-up 
procedures.
Exclusion criteria
 ► Patients for whom MRI is contraindicated due to:
 – non-compliant heart pacemaker or defibrillator
 – non-compliant metallic foreign body, for example, 
in one or both eyes and aneurysm clips in the brain
 – claustrophobia (eg, difficulty in an elevator or tele-
phone box).
 ► Patients not suitable for a thigh tourniquet (eg, 
peripheral vascular disease).
 ► Previous participation in the SAFE-TKR study.
Patients already scheduled for TKR surgery will be 
screened based on the eligibility criteria. A trained 
research associate will contact potentially eligible patients 
via telephone. Patients who are interested in taking 
part in the study will then be sent a patient information 
sheet and consent form and a date arranged to answer 
any further questions about the study and take consent. 
Verbal consent will initially be taken, followed by signed 
written consent via post or in person depending on the 
patient’s preference (see online supplementary appendix 
1 and 2).
Randomisation
All patients who consent to the trial will be registered and 
then undergo a preoperative MRI of their brain. Patients 
will be allocated 1:1 via Warwick randomisation service 
(independent of the study team) to either TKR surgery 
with tourniquet or TKR surgery without tourniquet 
using minimisation to ensure balance between the treat-
ment arms as regards patients with a history of VTE.13 
To ensure allocation concealment, following enrolment 
patient details are entered on a web-based form, and the 
treatment allocation are generated.
Planned intervention
Patients will undergo routine elective primary unilateral 
TKR (cemented) using the standard technique of the 
anaesthetist and the operating surgeon. Both groups will 
have a thigh tourniquet applied to the relevant lower 
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limb. Once the patient is fully anaesthetised, one of the 
following interventions will be applied:
Group A (tourniquet inflated)
The tourniquet will be inflated prior to the surgeon 
creating a wound, and only deflated once the procedure 
is deemed completed by the surgeon (at a minimum this 
will be after all the TKR components have been finally 
inserted).
Group B (tourniquet not inflated)
The tourniquet will not be inflated during the procedure.
In line with National Institute for Health and Care 
Excellence (NICE) guidance, all patients will receive 
the following routine chemical and mechanical VTE 
prophylaxis:
 ► intermittent pneumatic calf compression until 
patient’s mobility is no longer significantly reduced
 ► low molecular weight heparin (or unfractionated 
heparin for patients with severe renal impairment 
or established renal failure), started 6–12 hours after 
surgery and continued for 14 days postoperatively.
Clinical outcomes and time points
Primary clinical outcome
The primary clinical outcome will be evidence of new 
acute ischaemic brain lesions on MRI. The total number 
and volume of acute brain lesions detected on MRI 
per patient will be recorded. Presurgery MRIs will be 
obtained no more than 60 days before surgery, and post-
surgery MRIs will be obtained up to 2 days after surgery. 
Diffuse-weighted MRI is the most powerful tool for diag-
nosing acute ischaemic brain lesion caused by cerebral 
microembolism providing high level of sensitivity and 
specificity.14–16 The MRIs will all follow a standardised 
protocol including fast spin-echo fluid-attenuated inver-
sion recovery sequences and diffusion-weighted spin 
echo-echo planar imaging. The diffusion-weighted 
sequence will consist of an initial T2-weighted acquisition 
followed by a second acquisition with the application of 
diffusion-sensitising gradients in the three orthogonal 
directions. Lesions will also be described according to 
the vascular territory (anterior, middle, posterior cere-
bral arteries or vertebrobasilar arteries), side and type 
(cortical vs subcortical or deep grey matter). A planimetry 
of each lesion will be performed by using a grid overlay 
(using Image Processing and Analysis in Java software, 
National Institutes of Health) and by calculating lesion 
volume by multiplying the number of involved grids by 
the slice thickness and slice gap. Attack rate (presence 
of new lesions/number of patients) will also be calcu-
lated. A new lesion will be defined as a focal hyperintense 
area detected by the fluid-attenuated inversion recovery 
sequence, corresponding to a restricted diffusion signal 
in the diffusion-weighted imaging sequence.17 Scans 
will be read and evaluated by two experienced consul-
tant radiologists blinded to the timing of the imaging, 
allocated intervention and the neurological status of 
the patient. Even asymptomatic cerebral emboli, which 
may be detected using this approach, are associated with 
gradual memory impairment and cognitive decline.18–20
Secondary outcomes
1. MoCA preoperatively and days 1, 2 and 1 week post-
operatively: the MoCA is a brief cognitive screening 
tool with high sensitivity and specificity for detecting 
mild cognitive impairment.21
2. OCS preoperatively and days 1, 2 and 1 week post-
operatively: the OCS has higher sensitivity than the 
MOCA for measuring cognitive deficits associated 
with stroke (spatial disorders and apraxia), and it 
provides response speed as well as accuracy mea-
sures, so that indices such as processing speed can be 
derived.22
3. MMSE scores preoperatively and days 1, 2 and 1 week 
postoperatively: the MMSE is the most commonly 
used tool for measuring cognitive impairment and 
has been used extensively to measure disturbances in 
postoperative cognition.23–25
4. Acute thigh pain preoperatively and on days 1, 2 and 
1 week postoperatively: the 100 mm visual analogue 
scale (VAS) with 0 being no pain and 100 mm being 
the worst pain is a validated patient-reported out-
come measure for pain following TKR surgery.26
5. Oxford Knee Score (OKS) preoperatively and at 
1 week, 6 and 12 months postoperatively: this is a 
self-administered, validated knee replacement com-
posite outcome measure of knee pain and function 
consisting of 12 items. The score ranges from 12 to 
60, where 12 represents the best outcome and 60 rep-
resents the worst outcome.27
6. Five-level EuroQol-5D (EQ-5D-5L) scores preoper-
atively and at 1 week, six and 12 months postopera-
tively: This is a validated measure of health-related 
quality of life, consisting of a five-dimension health 
status classification system and a separate VAS. EQ-
5D-5L is primarily designed for self-completion by 
respondents and suited for use in postal surveys, in 
clinics and face-to-face interviews. It is cognitively 
simple, taking only a few minutes to complete.28 29
7. Number of symptomatic VTE events up to 12 months 
postoperatively: symptomatic VTE events will 
be defined based on NICE guidance: deep vein 
thrombosis=swollen or painful leg and a positive 
proximal leg vein ultrasound scan; pulmonary embo-
lism=chest pain, shortness of breath or haemoptysis 
and positive CT pulmonary angiogram (CTPA) scan 
or ventilation perfusion single photon emission com-
puted tomography (V/Q SPECT) or planar scan if 
CTPA not available. Symptomatic VTEs will be cap-
tured throughout the postoperative period via hos-
pital records. In addition, patient questionnaires at 6 
and 12 months will capture further data.
8. Surgical complications up to 12 months postopera-
tively: patient questionnaires and healthcare records 
will collect adverse events (AEs) that are deemed to 
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be as a direct result of surgery. Two blinded research-
ers will determine whether AEs should be classified as 
a surgical complication, where there is disagreement, 
a third researcher will determine the final allocation.
9. Number of intraoperative/postoperative blood trans-
fusions until discharge: data will be obtained from 
hospital records and recorded as number of units 
transfused.
10. Change in haemoglobin concentration (Hb 
g/L): routinely collected haemoglobin concentra-
tions (Hb g/L) measured from a full blood count 
taken on days 1–3 postoperatively (the sample clos-
est to day 1 will be favoured) will be subtracted from 
a preoperative (Hb g/L) measured within 3 months 
(the sample closest to the date of surgery will be 
favoured).
11. Revision rate of the TKR prosthesis at 12 months: re-
vision of the prosthesis for any reason will be estab-
lished by patient questionnaires at 12 months and 
hospital records.
12. All-cause mortality rates at 12 months: all baseline 
data will be summarised descriptively by interven-
tion group. The flow of patients through the trial will 
be presented in a CONSORT diagram, and patients 
withdrawn are summarised by treatment group.
Assessment and blinding
It will not be possible to blind the clinicians adminis-
tering the intervention. Patients and research associates 
collecting outcome measures will be blinded to treat-
ment allocation. Patients with any outstanding postoper-
ative cognitive tests (typically either day 2 or day 7) after 
discharge from hospital will have these administered by 
a trained research associate visiting them at home or an 
agreed location. Patients will receive a follow-up tele-
phone call at 6 weeks to record any VTEs since surgery. 
OKS, EQ-5D and complications questionnaire will be 
posted to the patient at 6 and 12 months. We will use tech-
niques common in long-term cohort studies to ensure 
minimum loss to follow-up, such as collection of next of 
kin contact addresses and telephone numbers, mobile 
telephone numbers and email addresses. A maximum of 
three attempts will be made acquire outcome data at each 
time point.
sample size calculation
As this is a pilot trial and not designed to measure effect, 
a formal sample size calculation is not required (the 
statistical analysis will be largely descriptive). We propose 
seeking to recruit and obtain primary clinical outcome 
data for 50 patients for descriptive analysis.
statistical analysis
Standard descriptive statistics (eg, medians and ranges or 
means and variances, dependent on the distribution of 
the outcome) and graphical plots showing correlations 
will be presented for the primary and secondary outcome 
measures. Baseline data will be summarised to check 
comparability between treatment arms and to highlight 
any characteristic differences between those individuals 
in the trial, those ineligible and those eligible but with-
holding consent. Exploratory analyses using regression 
techniques will be used to assess change in total volume 
of acute brain lesions in the two treatment groups and 
investigate the relationship between cognitive test scores 
and total volume of acute brain lesions. Linear regression 
will also be used to estimate the proportion of the vari-
ation in total volume of acute brain lesions that may be 
explained by change in cognition score between baseline 
and first postoperative assessment. To further investigate 
the extent to which cognition score is a surrogate for total 
volume of acute brain lesions, we will use logistic regres-
sion to predict treatment group from change in the total 
volume of acute brain lesions. The relationship between 
cognitive symptoms and the MRI data will also be evalu-
ated using voxel-based lesion-symptom mapping, where 
MRI intensity changes are associated to cognitive defi-
cits using either classification scores (deficit or not) or 
continuous measures of cognition.
The routine statistical analysis will mainly be carried out 
using STATA V.15 (Data Analysis and Statistical Software).
data management
After baseline demographic data is collected, a unique 
trial number will identify patients. All data collected will 
be entered into a secure trial database held at Warwick 
Clinical Trials Unit (WCTU). Identifiable patient infor-
mation will be held in a locked filing cabinet and coded 
with a patient trial number. The WCTU quality assurance 
manager will audit trial records in accordance with stan-
dard operating procedures. Outcomes will not be anal-
ysed until all primary outcome data are collected.
trial oversight
The Trial Management Group (TMG), consisting of the 
staff involved in the day-to-day running of the study, will 
meet monthly. Significant issues arising from manage-
ment meetings will be referred to the Trial Steering 
Committee (TSC) as appropriate. The trial will be 
guided by a TSC, a group of respected and experienced 
personnel and trialists as well as lay representatives. The 
TSC will have an independent chairperson. At least two 
formal TSC meetings will be held—one before the trial 
starts and one before recruitment to the trial completes. 
As this is a small feasibility study, there will not be a 
data monitoring committee. AEs and serious AEs will 
be monitored by the investigators. AEs will be assessed 
for causality within 24 hours of notification and patients 
followed up as per protocol. The trial may be stopped 
prematurely if mandated by ethics committee, a major 
unexpected safety concern arises or funding ceases. Any 
proposed changes to the protocol will first be reviewed 
by the TSC and, if approved, it will be submitted to the 
trial sponsor, funding body and local research ethics 
committee. All approved protocols will be marked by 
a version number and date. Requests for access to the 
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final dataset will be overseen by the TSC. Reasonable 
requests will then be given access to a full anonymised 
dataset.
Patient and public involvement (PPI)
The study has a PPI group that includes two patients (CG 
and JS) who have previously undergone TKR surgery 
and have experience of the intervention being evalu-
ated and its burden on patients. The study also has one 
public member (JD). The PPI group helped develop 
this study protocol, the associated patient information 
material and the outcome measures to be used through 
an active participation in both TMG and TSC meetings. 
The PPI group critically evaluate study progress and are 
active study collaborators alongside other members of the 
research team. The PPI group have taken part in training 
events to help them participate fully as members of the 
study team. The PPI group will facilitate the preparation 
of information about the results of this study and any 
future planned larger scale study to inform participants 
of this study, pateints and the wider public. This infor-
mation will be disseminated through a mixture of social 
media, written information sheets and peer-reviewed 
published papers.
IntEgrAtEd quAlItAtIvE rEsEArCh study
Method
Patients
In-depth semistructured interviews among with 
randomised patients and potential patients who decline 
to take part in the pilot trial will help understand people’s 
views regarding participation in the pilot trial. A purpo-
sive sample of around 30 people (evenly split between 
recruited and not recruited) will be interviewed, based 
on patient demographics (including age, gender and 
socioeconomic status).30 31 Patients will be recruited by 
a trained research associate and interviews will then be 
undertaken at a time convenient to the patient.
Surgeons
A survey will be undertaken among surgeons who routinely 
do TKR surgery. The survey will help gauge the extent to 
which this community is in clinical equipoise and would 
be willing to engage with and support a larger trial. We 
will use a web-based survey of members of the British 
Association for Surgery of the Knee (BASK). BASK has a 
UK membership of over 100 practising knee surgeons of 
whom the majority routinely undertake TKR surgery. A 
sample of at least 20 BASK surgeons (both those clearly 
in equipoise and those that are not) will be invited to take 
part in more in-depth qualitative interviews. We will use 
the general theory of implementation to investigate and 
understand the core constructs of sense-making processes 
of patients and surgeons regarding the feasibility of a full 
trial and to help understand any barriers and enablers for 
a larger trial.
Digital audio recordings of interviews will be tran-
scribed verbatim, checked and anonymised. Data will 
be managed and shared using NVivo analysis software. 
The analysis will be informed by a constant compara-
tive approach, where early analysis informs subsequent 
data collection, and data analysis takes place alongside 
data collection.30 This means insights from patients and 
surgeons can be explored further in the ongoing inter-
views. Data are coded from the start of data collection, 
and new data are compared with existing data. Codes are 
compared; categories are constructed and explored to 
ensure they are robust and then they are linked with rele-
vant theoretical literature. A technique of triangulation 
protocol will be used to facilitate the integration of the 
findings of the qualitative research with the quantitative 
data, thereby helping to determine the overall feasibility 
of a full trial.32 The data from patient interviews will also 
be used to help design optimal patient information mate-
rials for a larger trial.
MultICEntrE Cohort study
The National Joint Registry (NJR) is a population-based 
registry of joint replacements in the UK and covers both 
the NHS and private sectors. From April 2003 to December 
2003, the NJR collected data on the use of tourniquets for 
TKR surgery in England and Wales. At this stage, there 
were 406 hospitals listed within the NJR system (NHS 
hospitals, independent sector hospitals and treatment 
centres—both NHS funded and privately funded) and of 
these, 384 returned data (ie, 94%). The NJR dataset also 
contains many other key variables that are known to affect 
mortality, implant survivorship (revision rate) and the risk 
of VTE (1) use and type of VTE prophylaxis (such as low 
molecular weight heparin, aspirin and intermittent calf 
pump), (2) type of implant used, (3) use of cement and 
(4) basic patient demographics including age, body mass 
index (BMI) and American Society of Anesthesiologists 
(ASA) grade.
Method
We will access NJR data for the period in which tourni-
quet use was collected as part of the minimum dataset 
standard for knee replacement surgery: April 2003 to 
December 2003. We will analyse only data from primary 
cemented TKRs. Tourniquet use along with other 
routinely collected NJR baseline variables—age at time of 
surgery, sex and ASA classification—will be analysed to 
measure for independent effects on all cause revision. A 
tourniquet will be classed as used if even for a selective 
period of the procedure such as cementation. Sociode-
mographics, comorbidities, VTEs, cerebrovascular acci-
dent (CVAs or stroke) and length of hospital stay will 
be obtained by using patient identifiers (NHS number, 
gender, date of birth, postcode, procedure code and local 
patient identifier code) from the NJR to link the data 
to the Hospital Episode Statistics (HES) database. The 
HES data will provide details of VTE, sociodemographics, 
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comorbidities and hospital length of stay for the TKR. 
The study will specifically estimate differences between 
groups (tourniquet or no tourniquet) for the following:
baseline characteristics (age, BMI, ASA, comorbidi-
ties, type of VTE prophylaxis, type of implant and so-
ciodemographics)
all-cause mortality up to 12 months
length of inpatient hospital stay
risk of surgical complications up to 30 days
risk of VTE up to 12 months
risk of CVA up to 12 months
risk of revision at 1, 5 and 10 years.
statistical Analysis
The Kaplan-Meier method will be used to calculate 
mortality and revision rates in those who underwent 
TKR with and without a tourniquet. Multivariate logistic 
regression will be used to assess the effect of age, BMI, 
socioeconomic status, tourniquet use, type of VTE prophy-
laxis, ASA grade, comorbidities and type of TKR implant 
(cemented or uncemented) on risk of VTE, CVA and risk 
of revision. The results of these analyses will inform the 
planning of a subsequent definitive full trial, if such a trial 
is feasible.
ConClusIons: sAfEty And fEAsIbIlIty EvAluAtIon And 
PAthwAy to A full trIAl
A workshop will be held at the end of the feasibility study, 
involving key stakeholders (approximately 30 partici-
pants), patients, surgeons, researchers, allied health-
care professionals and healthcare policy makers. The 
workshop will have an independent chairperson. Using 
consensus conference methodology, delegates will be 
presented with results from the pilot RCT, retrospective 
multicentre cohort study, existing published data and 
where applicable pooled data from all three sources. The 
purpose will be to agree a consensus statement on the 
appropriateness and feasibility of proceeding to a full 
trial and the most appropriate primary outcome measure 
for a full trial.
A full definitive trial will be deemed feasible if:
the pilot RCT and integrated qualitative study suggest 
patients can be recruited and surgeons are prepared 
to perform surgery with or without a tourniquet;
and 
 ► the pilot trial identifies either a measure of cognitive 
brain function that accurately reflects symptomatic 
brain emboli or an alternative primary/coprimary 
outcome measure is identified such as pain, sympto-
matic VTE, revision rates OKS or EQ5D-5L scores that 
can be accurately and robustly collected in a full trial;
and 
 ► key stakeholders (patients, surgeons, public repre-
sentatives and researchers) agree at an end of study 
consensus conference that in light of the feasibility 
study and existing published research there remains 
insufficient data to make recommendations about the 
safety and clinical effectiveness of tourniquets and 
that a full trial is feasible and there is an appropriate 
primary/coprimary outcome measure for assessment.
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